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Background
Hypersensitivity reactions to carbamazepine (CBZ) have
been shown to be strongly associated with specific
human leukocyte antigen (HLA) alleles, with carriers of
the HLA alleles presenting an increased risk of develop-
ing hypersensitivity. HLA-B*15:02 was detected in
almost all cases of CBZ-induced Stevens-Johnson syn-
drome (SJS) in patients of Han Chinese or South-East
Asian ancestry, and its functional role in CBZ-induced
SJS has been well characterised. HLA-A*3101 is asso-
ciated with all clinical phenotypes of CBZ-induced
hypersensitivity in Caucasian and Japanese patients.
However, functional studies investigating the role of
HLA-A*31:01 in CBZ-specific T-cell responses have not
been performed. Furthermore, CBZ-specific T-cells of
CD4+ and CD8+ phenotype are readily detectable in
Caucasian patients, which is in stark contrast to the
dominant CD8+ T-cell response in Han Chinese. In this
study we therefore investigated the HLA restriction of
CBZ-reactive T-cells from a HLA-A*31:01 positive CBZ
hypersensitive patient, focusing on both the CD4+ and
CD8+ cells.
Method
Drug-specific T-cell clones (TCC) were generated by
serial dilution, and their reactivity to CBZ measured by
proliferation assay. HLA restriction of TCC was assessed
using anti-HLA antibodies as well as allogeneic HLA-
mismatched antigen-presenting cells (APC).
Results
Activation of CD8+ TCC could be blocked by an anti-
HLA class I antibody, and also when an anti-HLA A30/
A31 antibody was used. Using allogeneic HLA-A*31:01+
APC and control APC expressing common HLA-A
alleles, a CBZ-specific HLA-A*31:01 dependent activa-
tion of CD8+ TCC could be demonstrated. CBZ reactiv-
ity of CD4+ TCC was restricted by HLA class II,
predominantly HLA-DR and HLA-DP. CD4+ TCC pro-
liferated in the presence of CBZ and APC expressing
HLA-DRB1*04:04, an HLA class II allele known to be
part of a common haplotype with HLA-A*31:01 in Cau-
casians. APCs expressing other HLA-DRB1 alleles were
unable to stimulate a response.
Conclusion
We were able to characterise the individual HLA restric-
tion profile of CBZ-specific CD4+ and CD8+TCC from an
HLA-A*31:01+ patient. We discovered an HLA class II
allele, i.e. HLA-DRB1*04:04, to be functionally important
for the activation of CD4+ T-cells. The strong linkage
disequilibrium between the two alleles suggests a common
haplotype may contribute to the multi-clonal response
seen in Caucasian patients hypersensitive to CBZ.
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